Breaking News Instant updates and real-time market news.

2022-01-27 06:46:25 GOOG Alphabet $2,584.63 / +48.885 (+1.93%) , GOOGL Alphabet Class A $2,582.05 / +40.4 (+1.59%) … 06:46 01/27/22 01/27 06:46 01/27/22 06:46	Verily, GSK reach milestone in RA neuromodulation, first patient implant Five years ago, Verily, a subsidiary of Alphabet (GOOG;GOOGL), and GlaxoSmithKline (GSK) announced they were forming a new research and development-focused company, Galvani Bioelectronics. This new venture would be dedicated to treating chronic conditions, including Rheumatoid Arthritis, RA, through targeted neuromodulation therapies. Yesterday, the companies announced the successful implantation of the first-ever investigational treatment for RA through stimulation of the splenic nerve in a patient. The Galvani neurostimulator is designed to be implanted in a minimally invasive outpatient procedure. After implantation the patient and their care provider are then able to control, monitor, and charge the device as needed to ensure continued potential efficacy. In November 2021, a team of laparoscopic surgeons successfully completed the first implantation of a Galvani device in a patient. Over the last month, therapy was initiated as part of a small clinical study at the NHS Greater Glasgow and Clyde Health Board. At the same time, Galvani has also kicked off a larger U.S.-based study under approval from the FDA. This study will assess the safety and effectiveness of the Galvani platform in the RA patient population. GOOG Alphabet $2,584.63 / +48.885 (+1.93%) GOOGL Alphabet Class A $2,582.05 / +40.4 (+1.59%) GSK GlaxoSmithKline $44.18 / -0.18 (-0.41%)	01 Feb 01 Feb 09 Feb 27 Mar 03 Jun

2022-01-27 06:46:25

GOOG

Alphabet

$2,584.63 / +48.885 (+1.93%)

, GOOGL

Alphabet Class A

$2,582.05 / +40.4 (+1.59%)

… 06:46

01/27/22

01/27

06:46

01/27/22

06:46

Verily, GSK reach milestone in RA neuromodulation, first patient implant

Five years ago, Verily, a subsidiary of Alphabet (GOOG;GOOGL), and GlaxoSmithKline (GSK) announced they were forming a new research and development-focused company, Galvani Bioelectronics. This new venture would be dedicated to treating chronic conditions, including Rheumatoid Arthritis, RA, through targeted neuromodulation therapies. Yesterday, the companies announced the successful implantation of the first-ever investigational treatment for RA through stimulation of the splenic nerve in a patient. The Galvani neurostimulator is designed to be implanted in a minimally invasive outpatient procedure. After implantation the patient and their care provider are then able to control, monitor, and charge the device as needed to ensure continued potential efficacy. In November 2021, a team of laparoscopic surgeons successfully completed the first implantation of a Galvani device in a patient. Over the last month, therapy was initiated as part of a small clinical study at the NHS Greater Glasgow and Clyde Health Board. At the same time, Galvani has also kicked off a larger U.S.-based study under approval from the FDA. This study will assess the safety and effectiveness of the Galvani platform in the RA patient population.

GOOG

Alphabet

$2,584.63 / +48.885 (+1.93%)

GOOGL

Alphabet Class A

$2,582.05 / +40.4 (+1.59%)

GSK

GlaxoSmithKline

$44.18 / -0.18 (-0.41%)

01
Feb
01
Feb
09
Feb
27
Mar
03
Jun

OTHER BREAKING NEWS FROM THE FLY

Downgrade	JBG Smith downgraded to Peer Perform from Outperform at Wolfe Research » 06:33 05/23/22 05/23 06:33 05/23/22 06:33 JBGS JBG Smith Properties $24.97 / +0.045 (+0.18%) Wolfe Research analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research JBGS JBG Smith Properties $24.97 / +0.045 (+0.18%) 02/14/22 JBG Smith Properties forms office portfolio JV with Fortress Investment JBGS JBG Smith Properties $24.97 / +0.045 (+0.18%) 03/03/22 Evercore ISI Evercore ISI shakes up Office REIT ratings with one upgrade, two downgrades 07/12/21 BMO Capital JBG Smith Properties initiated with an Outperform at BMO Capital
Hot Stocks	ImmunoGen's BLA for mirvetuximab soravtansine in ovarian cancer accepted by FDA » 06:32 05/23/22 05/23 06:32 05/23/22 06:32 IMGN ImmunoGen $3.58 / +0.055 (+1.56%) ImmunoGen announced that… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events IMGN ImmunoGen $3.58 / +0.055 (+1.56%) 03/29/22 ImmunoGen submits BLA to FDA for mirvetuximab soravtansine 03/20/22 ImmunoGen presents full results from pivotal SORAYA trial 02/16/22 eFfector Therapeutics appoints Kristen Harrington-Smith to boardImmunoGen 02/15/22 ImmunoGen announces global licensing agreement with Eli Lilly IMGN ImmunoGen $3.58 / +0.055 (+1.56%) 03/21/22 RBC Capital ImmunoGen downgraded to Sector Perform from Outperform at RBC Capital 02/10/22 BMO Capital ImmunoGen initiated with an Outperform at BMO Capital 01/03/22 Guggenheim ImmunoGen, Merus named 'Best Ideas' in oncology-focused biotech at Guggenheim 12/01/21 Jefferies ImmunoGen upgraded to Buy at Jefferies after 'best-case data' in PROC IMGN ImmunoGen $3.58 / +0.055 (+1.56%) 05/06/22 ImmunoGen still sees 2022 revenue $75M-$85M, consensus $84.98M 05/06/22 ImmunoGen reports Q1 EPS (10c), consensus (21c) 02/25/22 ImmunoGen sees FY22 revenue $75M-$85M, consensus $63.61M 02/25/22 ImmunoGen reports Q4 EPS (17c), consensus ($1.71) 02 Dec IMGN ImmunoGen $3.58 / +0.055 (+1.56%) 03/21/22 What You Missed On Wall Street On Monday 03/21/22 What You Missed On Wall Street This Morning 03/21/22 Fly Intel: Pre-market Movers 12/01/21 Wall Street in Fives - Must Read Lists at Midday 06/03/22 2022 ASCO Annual Meeting 06/15/22 ImmunoGen, Inc.
Initiation	Johnson & Johnson assumed with an Outperform at SVB Leerink » 06:31 05/23/22 05/23 06:31 05/23/22 06:31 JNJ Johnson & Johnson $175.81 / +2.97 (+1.72%) SVB Leerink analyst David… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options JNJ Johnson & Johnson $175.81 / +2.97 (+1.72%) 05/18/22 Tesla ineligible for S&P 500 ESG Index inclusion, S&P announces 05/11/22 J&J appoints Thibaut Mongon as CEO Designate of new consumer health company 05/05/22 FDA limits authorized use of J&J's COVID vaccine 05/02/22 FDA announces tentative advisory committee meetings on COVID-19 vaccines JNJ Johnson & Johnson $175.81 / +2.97 (+1.72%) 05/17/22 BofA Teva upgraded to Neutral at BofA on potential opioid deal upside 05/17/22 Citi Johnson & Johnson price target lowered to $205 from $210 at Citi 04/29/22 Chardan Emergent BioSolutions price target lowered to $65 from $75 at Chardan 04/20/22 Credit Suisse Johnson & Johnson price target raised to $205 from $200 at Credit Suisse JNJ Johnson & Johnson $175.81 / +2.97 (+1.72%) 04/19/22 Johnson & Johnson cuts FY22 adj. EPS view to $10.15-$10.35 from $10.40-$10.60 04/19/22 Johnson & Johnson reports Q1 adjusted EPS $2.67, consensus $2.61 04/18/22 Notable companies reporting before tomorrow's open 04/18/22 Notable companies reporting before tomorrow's open JNJ Johnson & Johnson $175.81 / +2.97 (+1.72%) 05/10/22 Emergent plant's quality problems led to 400M discarded vaccines, WSJ reports 05/05/22 J&J sues SaveOnSP over use of drug cost assistance program, WSJ reports 04/27/22 J&J files suit against HIV-drug counterfeit distributors, WSJ reports 03/30/22 DOJ probes network accused of selling counterfeit HIV drugs, WSJ reports JNJ Johnson & Johnson $175.81 / +2.97 (+1.72%) 05/06/22 What You Missed On Wall Street On Friday 05/06/22 What You Missed On Wall Street This Morning 04/27/22 What You Missed On Wall Street On Wednesday 04/27/22 What You Missed On Wall Street This Morning 06/02/22 38th Annual Strategic Decisions Conference 09/07/22 2022 Wells Fargo Healthcare Conference 07/19/22 Johnson & Johnson - JNJ JNJ Johnson & Johnson $175.81 / +2.97 (+1.72%) 04/19/22 Unusually active option classes on open April 19th 01/25/22 Unusually active option classes on open January 25th 12/17/21 Unusually active option classes on open December 17th
Hot Stocks	Walmart, Symbotic expand partnership » 06:31 05/23/22 05/23 06:31 05/23/22 06:31 WMT Walmart $119.05 / -0.04 (-0.03%) Symbotic, an A.I.-powered… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options WMT Walmart $119.05 / -0.04 (-0.03%) 05/19/22 MeMD unveils name change to Walmart Health Virtual Care 05/17/22 Walmart falls -8.6% 05/17/22 Walmart falls -7.7% 05/17/22 Walmart CEO 'not happy with profit performance' in Q1 WMT Walmart $119.05 / -0.04 (-0.03%) 05/19/22 MKM Partners Target price target lowered to $180 from $253 at MKM Partners 05/19/22 Truist Best Buy price target lowered to $83 from $117 at Truist 05/19/22 Stifel Costco price target lowered to $515 from $565 at Stifel 05/18/22 BMO Capital Walmart price target lowered to $165 from $170 at BMO Capital WMT Walmart $119.05 / -0.04 (-0.03%) 05/17/22 Walmart cuts FY23 EPS view to flat from up 5%-6%, consensus $6.76 05/17/22 Walmart cuts Q2 EPS view to flat to up slightly from up low to mid single-digits 05/17/22 Walmart reports Q1 adjusted EPS $1.30, consensus $1.48 05/16/22 Notable companies reporting before tomorrow's open WMT Walmart $119.05 / -0.04 (-0.03%) 05/15/22 Walmart anticipates store manager shortage despite $200K-a-year pay, WSJ says 05/13/22 Perrigo sees infant formula shortages through rest of 2022, Reuters says 04/08/22 Walmart heir Walton set to make over $4B offer for Denver Broncos, NY Post says 04/08/22 Tata challenges Amazon, Flipkart with super app launch, DigiTimes reports WMT Walmart $119.05 / -0.04 (-0.03%) 05/17/22 What You Missed On Wall Street On Tuesday 05/17/22 What You Missed On Wall Street This Morning 05/17/22 Fly Intel: Pre-market Movers 05/16/22 What You Missed On Wall Street This Morning 08/16/22 Walmart - WMT 06/01/22 Wal-Mart Stores, Inc. WMT Walmart $119.05 / -0.04 (-0.03%) 05/18/22 Notable open interest changes for May 18th 05/17/22 Unusually active option classes on open May 17th 03/07/22 Wal-Mart call volume above normal and directionally bullish 03/04/22 Wal-Mart call volume above normal and directionally bullish
Recommendations	Baird a buyer into Petco Q1 results as shares offer good value » 06:31 05/23/22 05/23 06:31 05/23/22 06:31 WOOF Petco $15.11 / -1.655 (-9.87%) Baird analyst Peter… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events Options WOOF Petco $15.11 / -1.655 (-9.87%) 05/09/22 PetMed Express appoints Carden as VP of Product Management 05/05/22 Butterfly Network, Petco announce technology collaboration 05/02/22 Petco announces Backcountry x Petco pet gear collection 03/03/22 Petco to purchase remaining 50% stake in hospital joint venture WOOF Petco $15.11 / -1.655 (-9.87%) 05/20/22 Needham Petco seen as 'safe place to hide' on replenishment demand, says Needham 05/20/22 Jefferies Pet specialty retail selloff overdone, says Jefferies 05/16/22 Morgan Stanley Petco initiated with an Equal Weight at Morgan Stanley 05/13/22 Citi Petco price target lowered to $26 from $28 at Citi WOOF Petco $15.11 / -1.655 (-9.87%) 03/23/22 Petco sees long-term adjusted net income growth low double digits 03/23/22 Petco backs FY22 adjusted EPS 97c-$1.00, consensus 99c 03/08/22 Petco sees FY22 adjusted EPS 97c-$1.00, consensus 89c 03/08/22 Petco reports Q4 adjusted EPS 28c, consensus 25c 27 May WOOF Petco $15.11 / -1.655 (-9.87%) 05/16/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/13/22 Short Report: Upstart shorts take profits as stock craters on guidance cut 03/23/22 What You Missed On Wall Street On Wednesday 03/23/22 What You Missed On Wall Street This Morning 05/24/22 Petco - WOOF 06/08/22 Petco 06/28/22 Petco Health and Wellness Company, Inc. WOOF Petco $15.11 / -1.655 (-9.87%) 03/22/22 Largest borrow rate increases among liquid names 01/25/22 Largest borrow rate increases among liquid names

Recommendations	Mirum Pharmaceuticals price target raised to $69 from $64 at H.C. Wainwright » 06:30 05/23/22 05/23 06:30 05/23/22 06:30 MIRM Mirum Pharmaceuticals $25.67 / +1.46 (+6.03%) H.C. Wainwright analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research Earnings Events MIRM Mirum Pharmaceuticals $25.67 / +1.46 (+6.03%) 03/11/22 Raymond James Mirum Pharmaceuticals price target raised to $74 from $70 at Raymond James 10/11/21 Piper Sandler Mirum Pharmaceuticals remains undervalued despite catalysts, says Piper Sandler 09/30/21 H.C. Wainwright Mirum Pharmaceuticals price target raised to $64 from $51 at H.C. Wainwright 09/30/21 Raymond James Mirum Pharmaceuticals price target raised to $69 from $51 at Raymond James MIRM Mirum Pharmaceuticals $25.67 / +1.46 (+6.03%) 05/05/22 Mirum Pharmaceuticals reports Q1 EPS $(1.17), consensus ($1.34) 03/09/22 Mirum Pharmaceuticals reports Q4 revenue $3.14M 06/02/22 Mirum Pharmaceuticals, Inc.
Initiation	Gilead initiated with a Market Perform at SVB Leerink » 06:29 05/23/22 05/23 06:29 05/23/22 06:29 GILD Gilead $63.83 / +0.55 (+0.87%) SVB Leerink analyst David… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options GILD Gilead $63.83 / +0.55 (+0.87%) 05/18/22 Precision BioSciences publishes data from in vivo gene editing program 05/16/22 Gilead says FDA lifts clinical hold on investigational lenacapavir 05/02/22 Gilead, Dragonfly team to advance 'a number' of Dragonfly immunotherapies 04/25/22 Gilead confirms FDA approves sNDA to expand Veklury use to young children GILD Gilead $63.83 / +0.55 (+0.87%) 05/17/22 BMO Capital Scholar Rock price target lowered to $55 from $74 at BMO Capital 05/16/22 Piper Sandler Gilead price target lowered to $69 from $73 at Piper Sandler 04/29/22 Piper Sandler Gilead price target raised to $73 from $72 at Piper Sandler 04/12/22 Piper Sandler Gilead price target raised to $72 from $71 at Piper Sandler GILD Gilead $63.83 / +0.55 (+0.87%) 04/28/22 Gilead sees FY22 EPS at $6.20-$6.70, consensus $6.50 04/28/22 Gilead reports Q1 EPS $2.12, consensus $1.81 04/28/22 Notable companies reporting after market close 02/01/22 Gilead sees FY22 adjusted EPS $6.20-$6.70, consensus $6.91 GILD Gilead $63.83 / +0.55 (+0.87%) 03/30/22 DOJ probes network accused of selling counterfeit HIV drugs, WSJ reports 01/18/22 Gilead alleges counterfeiting network illegally sold HIV drugs, WSJ reports 11/30/21 Moderna CEO expects current vaccines to struggle with omicron, FT says 11/29/21 Pfizer to ask FDA to authorize 'extra doses' for 16 and 17 year olds, WaPo says GILD Gilead $63.83 / +0.55 (+0.87%) 04/25/22 What You Missed On Wall Street On Monday 02/28/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/02/22 Wall Street in Fives - Must Read Lists for Wednesday 02/02/22 Wall Street in Fives - Must Read Lists at Midday 06/02/22 38th Annual Strategic Decisions Conference 09/07/22 2022 Wells Fargo Healthcare Conference GILD Gilead $63.83 / +0.55 (+0.87%) 05/09/22 Gilead call volume above normal and directionally bullish 04/28/22 Gilead call volume above normal and directionally bullish 02/01/22 Gilead options imply 4.3% move in share price post-earnings 11/24/21 Gilead call volume above normal and directionally bullish
Upgrade	Saia upgraded to Buy from Neutral at UBS » 06:29 05/23/22 05/23 06:29 05/23/22 06:29 SAIA Saia / + UBS analyst Thomas… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly SAIA Saia / + 03/03/22 Saia reports January LTL shipments per workday increased 1.3% 03/02/22 Saia names Norwood as EVP, Chief Human Resources Officer 12/21/21 Saia partners with Daimler Trucks North America to test electric box vehicle 12/13/21 Saia expands George operations, opens new terminal north of Atlanta SAIA Saia / + 05/19/22 Citi Saia price target lowered to $190 from $230 at Citi 05/03/22 Wells Fargo Saia price target raised to $290 from $273 at Wells Fargo 04/20/22 Raymond James Saia price target lowered to $275 from $350 at Raymond James 04/08/22 BofA Saia downgraded to Neutral from Buy at BofA SAIA Saia / + 05/02/22 Saia reports Q1 EPS $2.98, consensus $2.71 02/02/22 Saia reports Q4 EPS $2.76, consensus $2.57 SAIA Saia / + 01/25/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
Recommendations	Boxed price target lowered to $12 from $13 at Citi » 06:28 05/23/22 05/23 06:28 05/23/22 06:28 BOXD Boxed $9.31 / -0.56 (-5.67%) Citi analyst Ronald Josey… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Options BOXD Boxed $9.31 / -0.56 (-5.67%) 05/12/22 Boxed enters multi-year collaboration with FedEx 05/06/22 Boxed appoints Anna Meyer as CRO, Veracelle Vega as CPO 03/21/22 Boxed falls -12.4% 12/31/21 Boxed falls -4.3% BOXD Boxed $9.31 / -0.56 (-5.67%) 04/19/22 Citi Boxed initiated with a Buy at Citi 01/04/22 BTIG Boxed initiated with a Neutral at BTIG 01/04/22 BTIG Boxed initiated with a Neutral at BTIG 11/03/21 DA Davidson Seven Oaks Acquisition initiated with a Buy at DA Davidson BOXD Boxed $9.31 / -0.56 (-5.67%) 05/13/22 Largest borrow rate increases among liquid names 04/07/22 Largest borrow rate increases among liquid names 03/25/22 Largest borrow rate increases among liquid names 03/02/22 Largest borrow rate increases among liquid names
Initiation	Ouster initiated with an Overweight at Cantor Fitzgerald » 06:28 05/23/22 05/23 06:28 05/23/22 06:28 OUST Ouster $2.37 / -0.095 (-3.85%) Cantor Fitzgerald analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options OUST Ouster $2.37 / -0.095 (-3.85%) 03/23/22 Ouster, Tacticaware launch joint security solution 03/03/22 Ouster in strategic customer pact with Third Wave Automation 01/20/22 Ouster in multi-year lidar pact with autonomous delivery firm Serve Robotics 01/11/22 Ouster, Vecna Robotics team amid acceleration of material handling automation OUST Ouster $2.37 / -0.095 (-3.85%) 03/31/22 Chardan Ouster initiated with a Buy at Chardan 02/16/22 Citi Ouster price target lowered to $17 from $19 at Citi 02/08/22 Craig-Hallum Velodyne stock 60% outperformance 'seems an overreaction,' says Craig-Hallum 01/24/22 Craig-Hallum Ouster price target lowered to $10 from $20 at Craig-Hallum OUST Ouster $2.37 / -0.095 (-3.85%) 05/03/22 Ouster backs FY22 revenue view $65M-$85M, consensus $74.67M 05/03/22 Ouster reports Q1 EPS (19c), consensus (16c) 02/15/22 Ouster reports Q4 EPS (17c), consensus (15c) OUST Ouster $2.37 / -0.095 (-3.85%) 02/15/22 Fly Intel: After-Hours Movers 05/25/22 22nd Annual Institutional Investor Conference 06/09/22 Ouster Inc OUST Ouster $2.37 / -0.095 (-3.85%) 02/15/22 Ouster Inc options imply 16.3% move in share price post-earnings

Recommendations	Applied Materials price target lowered to $160 from $175 at Citi » 06:27 05/23/22 05/23 06:27 05/23/22 06:27 AMAT Applied Materials $106.58 / -4.23 (-3.82%) Citi analyst Atif Malik… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options AMAT Applied Materials $106.58 / -4.23 (-3.82%) 04/21/22 Applied Materials introduces technologies enabling 2D scaling with EUV 04/14/22 Worldwide semiconductor revenue grew 26% in 2021, Gartner says 03/11/22 Applied Materials board increases quarterly dividend 8.3% to 26c per share 03/11/22 Applied Materials announces new $6B share repurchase authorization AMAT Applied Materials $106.58 / -4.23 (-3.82%) 05/20/22 Needham Applied Materials price target lowered to $130 from $172 at Needham 05/20/22 Craig-Hallum Applied Materials price target lowered to $145 from $170 at Craig-Hallum 05/20/22 DA Davidson Applied Materials price target lowered to $170 from $185 at DA Davidson 05/20/22 JPMorgan Applied Materials price target lowered to $158 from $174 at JPMorgan AMAT Applied Materials $106.58 / -4.23 (-3.82%) 05/19/22 Applied Materials sees Q3 adjusted EPS $1.59-$1.95, consensus $2.04 05/19/22 Applied Materials reports Q2 EPS $1.85, consensus $1.90 05/19/22 Notable companies reporting after market close 02/16/22 Applied Materials sees Q2 adjusted EPS $1.75-$2.05, consensus $1.94 AMAT Applied Materials $106.58 / -4.23 (-3.82%) 05/09/22 U.S. considering broader crackdown on Chinese chipmakers, Information reports 12/15/21 Biden administration considering tougher sanctions on SMIC, Bloomberg reports AMAT Applied Materials $106.58 / -4.23 (-3.82%) 05/20/22 What You Missed On Wall Street On Friday 05/20/22 What You Missed On Wall Street This Morning 05/20/22 Fly Intel: Pre-market Movers 05/19/22 Fly Intel: After-Hours Movers AMAT Applied Materials $106.58 / -4.23 (-3.82%) 05/19/22 Applied Materials options imply 6.3% move in share price post-earnings 05/19/22 Unusually active option classes on open May 19th 04/11/22 Applied Materials call volume above normal and directionally bullish 01/13/22 Applied Materials call volume above normal and directionally bullish
Upgrade	DTE Energy upgraded to Outperform from Neutral at Credit Suisse » 06:27 05/23/22 05/23 06:27 05/23/22 06:27 DTE DTE Energy $128.68 / -0.27 (-0.21%) Credit Suisse analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings DTE DTE Energy $128.68 / -0.27 (-0.21%) 04/28/22 Volta partners with State of Michigan and DTE Energy 03/29/22 DTE Energy, Lyft partner to make electric vehicles more accessible 03/22/22 DTE Energy adding several new MIGreenPower renewable energy projects 03/10/22 DTE Energy Chairman Gerry Anderson to retire, Jerry Norcia to succeed DTE DTE Energy $128.68 / -0.27 (-0.21%) 05/03/22 Citi DTE Energy price target raised to $146 from $134 at Citi 04/25/22 Credit Suisse DTE Energy initiated with a Neutral at Credit Suisse 03/11/22 UBS DTE Energy downgraded to Neutral from Buy at UBS 03/10/22 Argus DTE Energy price target raised to $132 from $130 at Argus DTE DTE Energy $128.68 / -0.27 (-0.21%) 04/28/22 DTE Energy reaffirms 2022 EPS view $5.80-$6.00, consensus $5.93 04/28/22 DTE Energy reports Q1 operating EPS $2.31, consensus $2.07 02/10/22 DTE Energy raises 2021 operating EPS view $5.80-$6.00 from $5.70-$5.97 02/10/22 DTE Energy reports Q4 operating EPS $1.05, consensus 84c
Recommendations	Alibaba price target lowered to $144 from $160 at Baird » 06:27 05/23/22 05/23 06:27 05/23/22 06:27 BABA Alibaba $86.82 / -0.89 (-1.01%) Baird analyst Colin… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options BABA Alibaba $86.82 / -0.89 (-1.01%) 05/16/22 Paulson exits Cerner, boosts Didi in Q1 03/22/22 Alibaba up 9.5% to $113.40 after the company expanded its buyback to $25B 03/21/22 Alibaba increases stock buyback program to $25B from $15B 03/10/22 BeiGene, Yum China, Zai Lab, ACM Research, Hutchmed named to SEC HFCAA list BABA Alibaba $86.82 / -0.89 (-1.01%) 05/18/22 Truist Alibaba price target lowered to $132 from $180 at Truist 05/16/22 JPMorgan Alibaba upgraded to Overweight from Underweight at JPMorgan 05/02/22 Mizuho Alibaba price target lowered to $160 from $180 at Mizuho 04/11/22 UBS Alibaba price target lowered to $140 from $150 at UBS BABA Alibaba $86.82 / -0.89 (-1.01%) 02/24/22 Alibaba reports Q4 EPS $2.65, consensus $2.55 02/23/22 Notable companies reporting before tomorrow's open 02/23/22 Notable companies reporting before tomorrow's open BABA Alibaba $86.82 / -0.89 (-1.01%) 04/29/22 China planning to 'pause' campaign against tech companies, WSJ reports 04/29/22 China tech stocks rally after report of Beijing ending regulatory clampdown 04/01/22 China considers giving U.S. full access to audits of most firms, Bloomberg says 03/28/22 Softbank's Alibaba shares in spotlight amid stock turbulence, WSJ reports BABA Alibaba $86.82 / -0.89 (-1.01%) 05/16/22 What You Missed On Wall Street On Monday 05/16/22 What You Missed On Wall Street This Morning 05/16/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/29/22 What You Missed On Wall Street On Friday 05/26/22 China Internet & Consumer 05/26/22 Alibaba - BABA BABA Alibaba $86.82 / -0.89 (-1.01%) 05/09/22 Alibaba call volume above normal and directionally bullish 04/28/22 Alibaba call buyer realizes 6% same-day gains 03/22/22 Unusually active option classes on open March 22nd 03/18/22 Notable open interest changes for March 18th
Recommendations	Paramount price target lowered to $44 from $47 at Citi » 06:26 05/23/22 05/23 06:26 05/23/22 06:26 PARA Paramount $32.66 / +0.43 (+1.33%) Citi analyst Jason… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options PARA Paramount $32.66 / +0.43 (+1.33%) 05/16/22 Berkshire Hathaway adds Citi, exits Wells Fargo in Q1 05/05/22 Paramount CEO says doesn't need M&A to add scale, will always look at options 05/03/22 Paramount says Paramount+ will launch in India via joint venture in 2023 04/19/22 Roku drops 6% to $109.96 after Netflix losses subscribers in Q1 PARA Paramount $32.66 / +0.43 (+1.33%) 05/04/22 Deutsche Bank Paramount price target lowered to $43 from $45 at Deutsche Bank 04/19/22 Rosenblatt Paramount initiated with a Sell at Rosenblatt 04/14/22 Deutsche Bank Paramount price target raised to $45 from $43 at Deutsche Bank 04/01/22 JPMorgan Paramount reinstated with a Neutral at JPMorgan PARA Paramount $32.66 / +0.43 (+1.33%) 05/03/22 Paramount reports Q1 EPS 60c, consensus 51c 05/02/22 Notable companies reporting before tomorrow's open 05/02/22 Notable companies reporting before tomorrow's open PARA Paramount $32.66 / +0.43 (+1.33%) 05/06/22 CBS CEO tries to boost moral after 'well-being survey' results, NY Post reports 04/04/22 'Sonic 2' film amasses $25.5M internationally, Gamesindustry.biz says 03/30/22 Hulu loses Paramount, MGM films as EPIX deal ends, The Streamable says 02/28/22 Discovery plans to name Chris Licht to lead CNN, WSJ reports PARA Paramount $32.66 / +0.43 (+1.33%) 05/22/22 Box Office Battle: 'Doctor Strange 2' wins weekend with another $31.6M 05/17/22 What You Missed On Wall Street On Tuesday 05/17/22 What You Missed On Wall Street This Morning 05/15/22 Box Office Battle: 'Doctor Strange 2' wins weekend with another $61M 00:00 Today 50th Annual Global Technology, Media & Communications Conference 05/25/22 Paramount - PARA 06/08/22 Paramount Global PARA Paramount $32.66 / +0.43 (+1.33%) 05/18/22 Paramount Global call volume above normal and directionally bullish 05/17/22 Early notable gainers among liquid option names on May 17th 05/17/22 Unusually active option classes on open May 17th 05/09/22 Paramount Global call volume above normal and directionally bullish
Initiation	Horizon Therapeutics initiated with a Market Perform at SVB Leerink » 06:26 05/23/22 05/23 06:26 05/23/22 06:26 HZNP Horizon Therapeutics $90.33 / +0.96 (+1.07%) SVB Leerink analyst David… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events HZNP Horizon Therapeutics $90.33 / +0.96 (+1.07%) 05/17/22 Horizon Therapeutics enrolls first patient in daxdilimab trial 05/16/22 Paulson exits Cerner, boosts Didi in Q1 05/11/22 Horizon Therapeutics launches letter-writing campaign for Thyroid Eye Disease 05/03/22 Horizon Therapeutics announces dazodalibep trial meets primary endpoint HZNP Horizon Therapeutics $90.33 / +0.96 (+1.07%) 03/14/22 Oppenheimer Horizon Therapeutics initiated with an Outperform at Oppenheimer 01/26/22 Piper Sandler Horizon Therapeutics price target lowered to $133 from $143 at Piper Sandler 01/18/22 JPMorgan Horizon Therapeutics valuation 'compelling' after selloff, says JPMorgan 12/08/21 Fly Intel: Top five analyst initiations HZNP Horizon Therapeutics $90.33 / +0.96 (+1.07%) 05/04/22 Horizon Therapeutics reports Q1 EPS $1.34, consensus $1.14 03/01/22 Horizon Therapeutics sees FY22 revenue $3.9B-$4B, consensus $3.91B 03/01/22 Horizon Therapeutics reports Q4 EPS $1.41, consensus $1.34 HZNP Horizon Therapeutics $90.33 / +0.96 (+1.07%) 03/01/22 Fly Intel: Pre-market Movers 07/07/22 PDUFA Date for KRYSTEXXA

Upgrade	Consolidated Edison upgraded to Neutral from Sell at Guggenheim » 06:26 05/23/22 05/23 06:26 05/23/22 06:26 ED Consolidated Edison $95.81 / +0.905 (+0.95%) Guggenheim analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate ED Consolidated Edison $95.81 / +0.905 (+0.95%) 01/20/22 Consolidated Edison raises annual dividend to $3.16 from $3.10 per share 12/30/21 W.Va regulators issue water quality certification for Mountain Valley Pipeline ED Consolidated Edison $95.81 / +0.905 (+0.95%) 05/03/22 Wells Fargo Wells Fargo downgrades Consolidated Edison to sell on 'tricky' NY rate case 05/02/22 Wells Fargo Consolidated Edison downgraded to Underweight from Equal Weight at Wells Fargo 04/25/22 Credit Suisse Consolidated Edison initiated with a Neutral at Credit Suisse 03/10/22 Mizuho Consolidated Edison price target raised to $94 from $90 at Mizuho ED Consolidated Edison $95.81 / +0.905 (+0.95%) 05/05/22 Consolidated Edison backs FY22 EPS view of $4.40-$4.60, consensus $4.49 05/05/22 Consolidated Edison reports Q1 EPS $1.47, consensus $1.48 02/17/22 Consolidated Edison reports Q4 operating revenue $3.42B, consensus $2.76B 02/17/22 Consolidated Edison sees FY22 adjusted EPS $4.40-$4.60, consensus $4.48 16 Jun
Recommendations	Dell Technologies price target lowered to $65 from $70 at Citi » 06:25 05/23/22 05/23 06:25 05/23/22 06:25 DELL Dell Technologies $40.05 / -1 (-2.44%) Citi analyst Jim Suva… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options DELL Dell Technologies $40.05 / -1 (-2.44%) 05/22/22 Fly Intel: Top five weekend stock stories 05/16/22 Elliott adds Diamond Offshore, exits Arconic in Q1 05/12/22 Arrow Electronics appoints Kirk Schell as president, global components 02/24/22 Dell Technologies initiates quarterly dividend of 33c per share DELL Dell Technologies $40.05 / -1 (-2.44%) 04/19/22 KGI Securities Dell Technologies initiated with a Neutral at KGI Securities 04/01/22 Goldman Sachs Dell Technologies downgraded to Neutral from Conviction Buy at Goldman Sachs 03/31/22 Barclays Dell Technologies price target lowered to $53 from $54 at Barclays 03/31/22 Morgan Stanley Dell Technologies downgraded to Equal Weight from Overweight at Morgan Stanley DELL Dell Technologies $40.05 / -1 (-2.44%) 02/24/22 Dell Technologies reports Q4 adjusted EPS $1.72, consensus $1.95 02/24/22 Notable companies reporting after market close 11/23/21 Dell Technologies reports Q3 adjusted EPS $2.37, consensus $2.18 11/23/21 Notable companies reporting after market close DELL Dell Technologies $40.05 / -1 (-2.44%) 05/22/22 Broadcom in talks to acquire VMware, Reuters reports 01/01/22 Amazon looks particularly attractive after wild year for tech, Barron's says DELL Dell Technologies $40.05 / -1 (-2.44%) 04/04/22 Fly Insider: TMC the Metals, Dell among week's notable insider trades 04/01/22 What You Missed On Wall Street On Friday 04/01/22 What You Missed On Wall Street This Morning 04/01/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/26/22 Dell Technologies - DELL 06/27/22 Dell Technologies Inc. CL C DELL Dell Technologies $40.05 / -1 (-2.44%) 11/23/21 Dell Technologies options imply 4.8% move in share price post-earnings
Recommendations	Marvell price target lowered to $80 from $95 at UBS » 06:24 05/23/22 05/23 06:24 05/23/22 06:24 MRVL Marvell $54.13 / -0.18 (-0.33%) UBS analyst Timothy… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options MRVL Marvell $54.13 / -0.18 (-0.33%) 05/09/22 Marvell to acquire Tanzanite in an all-cash transaction 04/20/22 Marvell appoints Sara Andrews to board of directors 04/14/22 Worldwide semiconductor revenue grew 26% in 2021, Gartner says 03/14/22 Marvell CEO: The company is performing extremely well MRVL Marvell $54.13 / -0.18 (-0.33%) 05/20/22 Oppenheimer Marvell price target lowered to $90 from $110 at Oppenheimer 05/17/22 Piper Sandler Piper moves to 'more positive stance' on semiconductor stocks 04/25/22 Raymond James Marvell upgraded to Outperform from Market Perform at Raymond James 04/25/22 Raymond James Marvell upgraded to Outperform from Market Perform at Raymond James MRVL Marvell $54.13 / -0.18 (-0.33%) 03/03/22 Marvell sees Q1 adjusted EPS 51c +/- 3c, consensus 50c 03/03/22 Marvell reports Q4 adjusted EPS 50c, consensus 48c 03/03/22 Notable companies reporting after market close 12/02/21 Marvell sees Q4 adjusted EPS 48c +/- 3c, consensus 42c MRVL Marvell $54.13 / -0.18 (-0.33%) 03/04/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/03/22 Fly Intel: After-Hours Movers 12/03/21 Wall Street in Fives - Must Read Lists for Friday 12/03/21 Wall Street in Fives - Must Read Lists at Midday 05/26/22 Marvell - MRVL 06/23/22 Marvell Technology Inc MRVL Marvell $54.13 / -0.18 (-0.33%) 04/28/22 Unusually active option classes on open April 28th 04/07/22 Marvell call buyer realizes 23% same-day gains 04/06/22 Marvell call volume above normal and directionally bullish 12/09/21 Marvell call volume above normal and directionally bullish
Recommendations	Foot Locker price target raised to $32 from $30 » 06:24 05/23/22 05/23 06:24 05/23/22 06:24 FL Foot Locker $31.52 / +1.22 (+4.03%) Baird analyst Jonathan… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options FL Foot Locker $31.52 / +1.22 (+4.03%) 05/20/22 Foot Locker rises 9.5% 05/20/22 Foot Locker sees FY22 comparable sales down 8%-10% 05/05/22 Foot Locker, Adidas announce new long-term strategic partnership 03/24/22 Foot Locker targets net zero GHG emissions by 2050 or sooner FL Foot Locker $31.52 / +1.22 (+4.03%) 05/16/22 Deutsche Bank Foot Locker price target lowered to $30 from $32 at Deutsche Bank 05/16/22 OTR Global Foot Locker downgraded to Mixed from Positive at OTR Global 03/28/22 Cowen Cowen cuts Foot Locker to Market Perform, more cautious following March data 03/28/22 Cowen Foot Locker downgraded to Market Perform from Outperform at Cowen FL Foot Locker $31.52 / +1.22 (+4.03%) 05/20/22 Foot Locker backs FY22 EPS $4.25-$4.60, consensus $4.41 05/20/22 Foot Locker reports Q1 EPS $1.60, consensus $1.55 05/19/22 Notable companies reporting before tomorrow's open 05/19/22 Notable companies reporting before tomorrow's open FL Foot Locker $31.52 / +1.22 (+4.03%) 03/05/22 Foot Locker has gotten hit hard, stock looks like a buy, Barron's says 03/02/22 Fanatics valued at $27B in latest fundraising, WSJ reports FL Foot Locker $31.52 / +1.22 (+4.03%) 05/20/22 What You Missed On Wall Street On Friday 05/20/22 What You Missed On Wall Street This Morning 05/20/22 Fly Intel: Pre-market Movers 03/28/22 What You Missed On Wall Street On Monday 05/24/22 6th Annual Future of the Consumer: Sustainable Growth for a New Ecosystem 08/19/22 Foot Locker - FL FL Foot Locker $31.52 / +1.22 (+4.03%) 05/20/22 Unusually active option classes on open May 20th 04/20/22 Foot Locker call volume above normal and directionally bullish 03/04/22 Foot Locker put volume heavy and directionally bearish 02/23/22 Unusually active option classes on open February 23rd
Initiation	AbbVie initiated with an Underperform at SVB Leerink » 06:23 05/23/22 05/23 06:23 05/23/22 06:23 ABBV AbbVie $151.04 / -0.8 (-0.53%) SVB Leerink analyst David… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options ABBV AbbVie $151.04 / -0.8 (-0.53%) 05:26 Today AbbVie receives CHMP recommendation for upadacitinib approval 05/20/22 AbbVie submits NDA to FDA for ABBV-951 05/16/22 Berkshire Hathaway adds Citi, exits Wells Fargo in Q1 05/16/22 AbbVie, Cugene announce collaboration in autoimmune diseases ABBV AbbVie $151.04 / -0.8 (-0.53%) 05/13/22 Piper Sandler Atopic dermatitis market looks 'increasingly crowded,' says Piper Sandler 05/06/22 Daiwa AbbVie downgraded to Neutral from Outperform at Daiwa 05/03/22 Morgan Stanley Vertex upgraded to Equal Weight at Morgan Stanley following AbbVie failure 05/02/22 Morgan Stanley AbbVie's recent weakness a buying opportunity, says Morgan Stanley ABBV AbbVie $151.04 / -0.8 (-0.53%) 04/29/22 AbbVie sees FY22 revenue $59.4B, consensus $60.22B 04/29/22 AbbVie sees Q2 adjusted EPS $3.38-$3.42, consensus $3.50 04/29/22 AbbVie cuts FY22 adjusted EPS view to $13.92-$14.12 from $14.00-$14.20 04/29/22 AbbVie reports Q1 adjusted EPS $3.16, consensus $3.14 ABBV AbbVie $151.04 / -0.8 (-0.53%) 05/10/22 Teva, Allergan offering over $5B to settle opioid suits, Bloomberg says 05/10/22 Teva, Allergan offering over $5B to settle opioid suits, Bloomberg says 03/07/22 Johnson & Johnson negotiating deals with two Chinese companies, FT reports ABBV AbbVie $151.04 / -0.8 (-0.53%) 05/10/22 What You Missed On Wall Street On Tuesday 05/03/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/02/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/29/22 What You Missed On Wall Street On Friday 06/02/22 38th Annual Strategic Decisions Conference 06/03/22 2022 ASCO Annual Meeting 09/07/22 2022 Wells Fargo Healthcare Conference ABBV AbbVie $151.04 / -0.8 (-0.53%) 04/29/22 Unusually active option classes on open April 29th 02/24/22 AbbVie put volume heavy and directionally bearish 01/24/22 AbbVie put volume heavy and directionally bearish 12/06/21 Unusually active option classes on open December 6th

Recommendations	Stealth Biotherapeutics price target lowered to $1.50 from $4 at H.C. Wainwright » 06:22 05/23/22 05/23 06:22 05/23/22 06:22 MITO Stealth Biotherapeutics / + H.C. Wainwright analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research MITO Stealth Biotherapeutics / + 05/12/22 Stealth Biotherapeutics granted FDA orphan designation for elamipretide 05/10/22 Stealth Biotherapeutics granted FDA Orphan Designation for DMD treatment 05/02/22 Stealth BioTherapeutics Corporation (ADS) trading resumes 05/02/22 Stealth BioTherapeutics Corporation (ADS) trading halted, news pending MITO Stealth Biotherapeutics / + 07/01/21 Maxim Stealth Biotherapeutics initiated with a Buy at Maxim 07/01/21 Maxim Stealth Biotherapeutics initiated with a Buy at Maxim
Recommendations	Zymeworks price target lowered to $40 from $44 at H.C. Wainwright » 06:21 05/23/22 05/23 06:21 05/23/22 06:21 ZYME Zymeworks $5.99 / +0.155 (+2.66%) H.C. Wainwright analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly ZYME Zymeworks $5.99 / +0.155 (+2.66%) 05/20/22 Zymeworks rejects unsolicited acquisition proposal from All Blue Falcons FZE 05/04/22 Zymeworks expects cash to fund operations into second half of 2023 04/29/22 Zymeworks rises 31.7% 04/29/22 Zymeworks rises 53.9% ZYME Zymeworks $5.99 / +0.155 (+2.66%) 05/09/22 Citi Zymeworks should reject 'opportunistic' $10.50 per share offer, says Citi 05/05/22 Guggenheim Zymeworks upgraded to Buy at Guggenheim amid low expectations 05/05/22 Guggenheim Zymeworks upgraded to Buy from Neutral at Guggenheim 03/15/22 Evercore ISI Zymeworks initiated with an Outperform at Evercore ISI ZYME Zymeworks $5.99 / +0.155 (+2.66%) 05/04/22 Zymeworks reports Q1 adjusted EPS ($1.17), consensus ($1.67) 02/24/22 Zymeworks reports Q4 EPS (95c), consensus ($1.14) 27 Jan ZYME Zymeworks $5.99 / +0.155 (+2.66%) 05/05/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/29/22 What You Missed On Wall Street On Friday 04/29/22 What You Missed On Wall Street This Morning 04/29/22 Fly Intel: Pre-market Movers
Recommendations	Atara Biotherapeutics price target lowered to $29 from $31 at H.C. Wainwright » 06:20 05/23/22 05/23 06:20 05/23/22 06:20 ATRA Atara Biotherapeutics $5.17 / +0.015 (+0.29%) H.C. Wainwright analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events ATRA Atara Biotherapeutics $5.17 / +0.015 (+0.29%) 05/19/22 Atara Biotherapeutics down 14% at $4.44 after announcing end of Bayer deal 05/19/22 Atara provides update on Bayer collaboration 05/05/22 Atara Bio sees cash, equivalents sufficient to fund operations into 4Q23 04/06/22 Applied Molecular Transport appoints Banard to board of directors ATRA Atara Biotherapeutics $5.17 / +0.015 (+0.29%) 05/09/22 Citi Citi downgrades Atara Biotherapeutics on lack of near-term drivers 05/09/22 Citi Atara Biotherapeutics downgraded to Neutral from Buy at Citi 03/28/22 JPMorgan Atara Biotherapeutics price target lowered to $22 from $27 at JPMorgan 03/08/22 Mizuho Atara Biotherapeutics price target lowered to $39 from $41 at Mizuho ATRA Atara Biotherapeutics $5.17 / +0.015 (+0.29%) 05/05/22 Atara Biotherapeutics reports Q1 EPS (87c), consensus (98c) 02/28/22 Atara Biotherapeutics reports Q4 EPS (96c), consensus (69c) 06/23/22 Atara Biotherapeutics, Inc.
Recommendations	Snowflake price target lowered to $180 from $260 at UBS » 06:20 05/23/22 05/23 06:20 05/23/22 06:20 SNOW Snowflake $141.51 / -5.36 (-3.65%) UBS analyst Karl… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options SNOW Snowflake $141.51 / -5.36 (-3.65%) 05/16/22 Lone Pine adds TSMC in Q1, exits KE Holdings and Adobe 05/16/22 Tiger Global buys Starry, exits Adobe in Q1 03/29/22 Snowflake extends relationship with AWS 03/06/22 Fly Intel: Top five weekend stock stories SNOW Snowflake $141.51 / -5.36 (-3.65%) 05/20/22 Barclays Snowflake price target lowered to $218 from $313 at Barclays 05/18/22 Mizuho Snowflake price target lowered to $225 from $370 at Mizuho 05/10/22 Truist Snowflake price target lowered to $300 from $350 at Truist 04/25/22 Wolfe Research Snowflake initiated with an Outperform at Wolfe Research SNOW Snowflake $141.51 / -5.36 (-3.65%) 03/02/22 Snowflake sees FY23 product revenue $1.88B-$1.9B 03/02/22 Snowflake reports Q4 EPS (43c), consensus 3c 03/02/22 Notable companies reporting after market close 12/01/21 Snowflake reports Q3 EPS (51c), consensus (6c) SNOW Snowflake $141.51 / -5.36 (-3.65%) 05/21/22 Some stocks that aren't as cheap as they look, Barron's says 03/05/22 Cloud stocks have become a haven in tech, Barron's says SNOW Snowflake $141.51 / -5.36 (-3.65%) 04/25/22 What You Missed On Wall Street On Monday 04/25/22 What You Missed On Wall Street This Morning 04/25/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/31/22 What You Missed On Wall Street On Thursday 05/26/22 Technology 05/25/22 Snowflake - SNOW SNOW Snowflake $141.51 / -5.36 (-3.65%) 05/20/22 Snowflake put volume heavy and directionally bearish 05/19/22 Snowflake call volume above normal and directionally bullish 04/29/22 Snowflake call volume above normal and directionally bullish 04/06/22 Snowflake put volume heavy and directionally bearish
Initiation	Amgen initiated with a Market Perform at SVB Leerink » 06:20 05/23/22 05/23 06:20 05/23/22 06:20 AMGN Amgen / + SVB Leerink analyst David… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options AMGN Amgen / + 05/16/22 Crispr Therapeutics appoints Morrow as CMO 05/04/22 BeiGene granted conditional approval of Blincyto by China NMPA 04/27/22 Amgen receives notice of deficiency from IRS for 2013-2015 period 04/27/22 Amgen's reports safety and efficacy results of Repatha Phase 3 studies AMGN Amgen / + 05/10/22 Mizuho Amgen price target raised to $208 from $202 at Mizuho 05/05/22 Stifel ASCO sets up as 'downside-biased' for Mirati investors, says Stifel 04/28/22 BMO Capital Amgen price target lowered to $243 from $263 at BMO Capital 04/28/22 Piper Sandler Amgen price target raised to $260 from $255 at Piper Sandler AMGN Amgen / + 04/27/22 Amgen backs FY22 adjusted EPS view $17.00-$18.00, consensus $17.63 04/27/22 Amgen reports Q1 adjusted EPS $4.25, consensus $4.10 04/27/22 Notable companies reporting after market close 02/08/22 Amgen sees FY22 revenue $25.4B-$26.5B, consensus $27B AMGN Amgen / + 03/07/22 Johnson & Johnson negotiating deals with two Chinese companies, FT reports 12/14/21 Moderna, Amgen among biotech companies pulling out of JPM conference, STAT says AMGN Amgen / + 04/28/22 What You Missed On Wall Street On Thursday 04/27/22 Fly Intel: After-Hours Movers 02/08/22 Wall Street in Fives - Must Read Lists for Tuesday 02/08/22 Wall Street in Fives - Must Read Lists at Midday 06/03/22 2022 ASCO Annual Meeting 06/21/22 Amgen AMGN Amgen / + 02/08/22 Early notable gainers among liquid option names on February 8th 01/03/22 Amgen call volume above normal and directionally bullish

Events

Earnings calls, analyst events, roadshows and more

XPEV
Today at 08:00

XPeng - XPEV Conference Calls
NIU
Today at 08:00

Niu Technologies - NIU Conference Calls
CAAS
Today at 08:00

China Automotive - CAAS Conference Calls
CSTE
Today at 08:00

Caesarstone Firm Sponsored Meetings

Virtual Meeting
JPM
Today at 08:00

JPMorgan Firm Sponsored Meetings

Virtual Meeting
Today at 08:30

Chicago Fed National Activity Index--3 Month Moving Average: April 2022 Government Event
Today at 08:30

Chicago Fed National Activity Index: April 2022 Government Event
RSLS
Today at 08:30

ReShape Lifesciences - RSLS Conference Calls
AVPT
Today at 09:00

AvePoint Firm Sponsored Meetings

Virtual Meeting
GILT
Today at 09:30

Gilat Satellite - GILT Conference Calls

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	No deals
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

Mon	No deals
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

View All Syndicate Announcements »

Verily, GSK reach milestone in RA neuromodulation, first patient implant

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access